Introduction {#s1}
============

Neuromyelitis optica spectrum disorder (NMOSD) is an uncommon inflammatory disease of the central nervous system, with clinical features of optic neuritis, myelitis, and certain brain, and brainstem syndromes. Although it had long been debated whether NMOSD is a severe variant of multiple sclerosis (MS), the discovery of NMOSD-specific aquaporin 4 (AQP4) antibody, and the subsequent clinical, immunological, and pathological data have established that NMOSD is indeed a distinct entity ([@B1]--[@B3]). Currently, cases clinically diagnosed as NMOSD may include AQP4-antibody-seropositive autoimmune astrocytopathic disease, myelin oligodendrocyte glycoprotein (MOG)-antibody-seropositive inflammatory demyelinating disease, and double-seronegative disease ([@B4]).

AQP4-antibody-seropositive NMOSD has a high female-to-male ratio (up to 9:1) ([@B5]), and its mean age at onset is around 40 years ([@B6], [@B7]), older than in MS. Pathologically, it is primarily an astrocytopathic disease rather than a demyelinating disease ([@B3], [@B8]). For MOG-antibody disease, the sex ratio is close to 1:1, and it is more common in children than in adults ([@B9], [@B10]). Its clinical manifestations overlap with those of AQP4-antibody disease but there are differences about which there is emerging consensus. Besides optic neuritis and myelitis, its clinical phenotypes also include acute or multiphasic disseminated encephalomyelitis (ADEM/MDEM), brainstem and cerebral cortical encephalitis, and cranial nerve involvement ([@B11]--[@B14]). Double (AQP4- and MOG-antibodies)-seronegative disease is enigmatic at present and requires further clinical and laboratory research for specific classification.

There have been several editions of the diagnostic criteria for NMOSD since 1999 ([@B15], [@B16]), with the latest being the 2015 International Panel on NMO Diagnosis (IPND) criteria ([@B17]). In the meantime, laboratory assays for AQP4 antibody and MOG antibody have also improved over time, with increased sensitivity and specificity ([@B18], [@B19]). These factors have contributed to the improvement in the accuracy of the diagnosis of NMOSD cases.

In this article, we review current data on the worldwide epidemiology of NMOSD, specifically on the population-based studies of NMOSD to determine its prevalence and incidence among different populations and racial groups. We emphasize that the field of NMOSD is undergoing a rapid evolution, making epidemiological estimates tentative. Additionally, different levels of diagnostic rigor to exclude NMOSD mimics and access to medical care in study populations can bias the epidemiological survey results in the disease, which makes the interpretation and comparison of the findings in and across the studies difficult. Nonetheless, the best known of current knowledge is being presented.

Search Strategy and Selection Criteria
--------------------------------------

The PubMed database was searched for population-based studies on NMOSD with prevalence data, from 1st January 2000 till 11th March 2020. A combination of the following search terms was used: "neuromyelitis optica," "NMO," "NMOSD," "aquaporin 4," "AQP4," "myelin oligodendrocyte glycoprotein," "MOG," "optico-spinal multiple sclerosis," "OSMS," "idiopathic inflammatory demyelinating disease," "IIDD," "epidemiology," "prevalence," "population," and "demographic." The reference lists in published articles on NMOSD were also queried to identify further studies. Additionally, recent conference proceedings of major neurology and MS congresses, including the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the Pan-Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS), were searched for relevant abstracts where the full studies are not yet published. Population-based studies with information on the prevalence of NMOSD in English language were reviewed. The final list of publications was selected on the basis of relevance to the topic.

Prevalence of NMOSD
-------------------

The prevalence range of NMOSD is \~0.5--4/100,000, and may be up to 10/100,000 in certain racial groups. Nevertheless, this prevalence range is rather small relative to that of MS, which ranges from 1--2/100,000 in the equatorial region, to 150--200/100,000 in Canada and northern part of Europe ([@B20], [@B21]).

Over the past two decades, population-based studies of NMOSD have provided important insights into its prevalence. The earliest population-based studies were conducted in French West Indies (Martinique) ([@B22], [@B23]), Cuba ([@B24]), Denmark ([@B25]), and Tokachi Province on Hokkaido Island in Japan ([@B26]). Interestingly, the majority of these early studies were conducted on island populations, which facilitate population-based studies by providing well-delimited boundaries of the study area. Two of the studies (Martinique and Hokkaido) ([@B22], [@B23], [@B26]) have since been updated by the original groups of researchers.

Since 2017, several new population-based studies were published, expanding knowledge of NMOSD in diverse populations around the world. Inter-racial variation in prevalence, as summarized in [Table 1](#T1){ref-type="table"}, is notable and consistent across geographical regions. More recently, the Australia/New Zealand group has also re-analyzed the data from their 2017 study ([@B47]) to provide further information with regards to the prevalence among different racial groups in their large continent ([@B46]). [Figure 1](#F1){ref-type="fig"} is a map showing population-based prevalence studies of NMOSD around the world.

###### 

Population-based prevalence and incidence studies of NMOSD.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Population-based study**                                  **Geographical location**     **Prevalence of NMOSD (per 100,000 population), as according to racial groups**   **Incidence (per million population)**   **AQP4-ab testing methods**   **AQP4-ab positivity**               **Female-to-male ratio**                                           
  ----------------------------------------------------------- ----------------------------- --------------------------------------------------------------------------------- ---------------------------------------- ----------------------------- ------------------------------------ -------------------------- -------------------------- ------------ -------------
  Cabrera-Gomez et al. (2009) ([@B24])                        Cuba                          0.43                                                                              0.80                                                                                                        0.53                       Not tested                 Not tested   7.3:1

  Asgari et al. (2011) ([@B25]) (re-analyzed 2019) ([@B27])   South Denmark                 1.68[^\*^](#TN1){ref-type="table-fn"}                                                                                                                                                         1.5                        CBA                        62%          5.3:1

  Cossburn et al. (2012) ([@B28])                             South East Wales              1.96                                                                                                                                                                                          NR                         NR                         71%          6:1

  Jacob et al. (2013) ([@B29])                                Merseyside, England           0.66[^\*^](#TN1){ref-type="table-fn"}                                             1.8[^\*^](#TN1){ref-type="table-fn"}                                                                        0.8                        Oxford CBA                 88%          3:1

  Aboul-Enein et al. (2013) ([@B30])                          Austria                       0.77                                                                                                                                                                                          0.54                       Innsbruck CBA              100%         7:1

  Pandit and Kundapur (2014) ([@B31])                         Mangalore, India                                                                                                                                                                       South Indians:\                      NR                         NR                         27%          1.2:1
                                                                                                                                                                                                                                                     2.6\                                                                                                    
                                                                                                                                                                                                                                                     (0.72 if using 2015 IPND criteria)                                                                      

  Etemadifar et al. (2014) ([@B32])                           Isfahan, Iran                 1.9                                                                                                                                                                                           NR                         NR                         66%          2.3:1

  Kashipazha et al. (2015) ([@B33])                           Khuzestan, Iran               1.1                                                                                                                                                                                           NR                         NR                         54%          7.5:1

  Flanagan et al. (2016) ([@B34])                             Olmsted county, USA           4.0                                                                               13.0                                                                                                        0.7                        Mayo CBA                   83%          5:1

                                                              French Martinique Island      6.1\                                                                              11.5                                                                                                        7.3                        Mayo CBA                   79%          8.8:1
                                                                                            (single case, AQP4-ab negative)                                                                                                                                                                                                                                  

  van Pelt et al. (2016) ([@B35])                             Netherlands                   ---                                                                                                                                                                                           0.9                        CBA                        NA           4.9:1

  Houzen et al. (2017) ([@B36])                               Tokachi, Hokkaido, Japan                                                                                                                                 Japanese: 4.1                                                      NR                         Sendai CBA                 79%          6:1

  Eskandarieh et al. (2017) ([@B37])                          Tehran, Iran                  0.86                                                                                                                                                                                          NR                         ELISA                      47%          5.1:1

  Sepúlveda et al. (2018) ([@B38])                            Catalonia                     0.89                                                                                                                                                                                          0.63                       Mainly CBA (96%)           73%          3.1:1

  Hor et al. (2018) ([@B39])                                  Penang Island, Malaysia                                                                                                                                  Chinese: 3.31                 Malays: 0.80\                        NR                         Euroimmun CBA              100%         14:1
                                                                                                                                                                                                                                                     (revised)                                                                                               

  Miyamoto et al. (2018) ([@B40])                             Japan (nationwide estimate)                                                                                                                              Japanese: 3.42                                                     NR                         NA                         NA           6.4:1

  Holroyd et al. (2018) ([@B41])                              Abu Dhabi, UAE                                                                                                                                                                         Arabs: 1.09                          1.16                       NR                         83%          All females

  Papp et al. (2018) ([@B42])                                 Denmark                       1.09[^\*^](#TN1){ref-type="table-fn"}                                                                                                                                                         0.70                       Various, incl. CBA         70%          4.5:1

  Jonsson et al. (2019) ([@B43])                              Sweden                        1.04                                                                                                                                                                                          0.79                       Immunoblot and CBA         NR           2.8:1

  Kim et al. (2019) ([@B44])                                  South Korea                                                                                                                                              Koreans: 2.56                                                      7.3                        CBA                        NA           2.37:1

  Papp et al. (2020) ([@B45])                                 Hungary                       Hungarians: 1.91[^\*^](#TN1){ref-type="table-fn"}                                                                                                                                             1.32                       CBA                        83%          8.8:1

  Bukhari et al.                                              Australia and                 0.55                                                                              1.84                                     Asians: 1.57                  0.37                                 IF tissue                  \>90%                      6:1          

  (PACTRIMS                                                   New Zealand                                                                                                                                                                            Māoris: 1.50                                                    assay,                                  

  2019\) ([@B46]) (updated from 2017 study) ([@B47])                                                                                                                                                                                                 Australian Aborigines: 0.38                                     some also ELISA and CBAs                

  Lee et al. (2020) ([@B48])                                  South Korea                                                                                                                                              Koreans: 3.56                                                      4.1--6.5                   NA                         NA           4.7:1
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Only consider adult population. (As AQP4-antibody-positive NMOSD is rare in children, thus, if full population is considered, the prevalence will be slightly lower)*.

*NMOSD, neuromyelitis optica spectrum disorder; AQP4-ab, aquaporin 4-antibody; CBA, cell-based assay; IF, immunofluorescence; NA, not applicable; NR, not reported*.
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### East Asians

East Asians (Japanese, Chinese, and Koreans) appear to have a higher prevalence of NMOSD (around 3.5/100,000) as compared to Whites and other Asian racial groups. The study in Hokkaido, Japan recorded a prevalence of 4.1/100,000 ([@B36]), while the Japanese nationwide survey estimated a prevalence of 3.42/100,000 ([@B40]). Meanwhile, a study conducted in the multi-racial population in Penang Island, Malaysia showed that the prevalence among Chinese was 3.31/100,000 ([@B39]). These results were in line with the genetic studies that showed that Japanese and Chinese share the same HLA risk genes for NMOSD, namely, HLA-DPB1^\*^05:01 and HLA-DRB1^\*^16:02 ([@B49]--[@B51]). In a very recent study from South Korea, by using a nationwide health insurance research dataset, it was calculated that the prevalence among Koreans was 3.56/100,000 in 2017 ([@B48]). More studies, especially from China, Taiwan, and Hong Kong will be useful to further inform the prevalence of NMOSD among the East Asians.

### Blacks

In 1971, a study conducted in a single hospital in the sub-Saharan African city of Ibadan (Nigeria) reported 95 cases of NMO, 22 cases of acute transverse myelitis, 11 cases of bilateral retrobulbar neuritis, and only two cases of MS over 12 years of hospital admissions (1957--1969) ([@B52]). During the same period, there were nine cases of non-Nigerians with MS (in eight Europeans and one Indian). It estimated that NMO cases made up 0.43/1000 (or 430/100,000) of the hospital population.

Population-based studies over the past two decades showed that Blacks also have a higher NMOSD prevalence than Whites. A study conducted in Liverpool, UK reported a prevalence rate of 1.8/100,000 among Blacks ([@B29]). The Australia/New Zealand study estimated a prevalence rate of 1.84/100,000 in those with African ancestry ([@B46]). The study conducted in the French Martinique Island in the Caribbean reported a very high prevalence of 11.5/100,000 among its Black population ([@B34]), and this was the highest prevalence reported so far. In population-based studies, within the same localities, prevalence among Blacks is always higher than in Whites, as seen in Cuba ([@B24]), Liverpool (UK) ([@B29]), Olmsted county (USA) ([@B34]), Martinique Island ([@B34]), and Australia/New Zealand ([@B46]).

As Blacks are genetically diverse, more data from different geographical regions are needed, and especially those from the African continent. Although no population-based studies of NMOSD have been published from Africa, recently there have been reports of NMOSD cases from various African countries that are to be compiled and reported elsewhere.

### Whites/Caucasians

In recent nationwide and region-wide studies, the prevalence of NMOSD among Whites has consistently been \~1/100,000. The prevalence was 0.55/100,000 in Australia and New Zealand ([@B46], [@B47]), 0.89/100,000 in Catalonia ([@B38]), 1.09/100,000 in Denmark ([@B42]), and 1.04/100,000 in Sweden ([@B43]). Also recently, a re-analysis of the data of an earlier study from South Denmark has reported the prevalence of AQP4-antibody-positive NMOSD as 1.68/100,000, and the prevalence of the total clinical phenotype including AQP4-antibody-negative and MOG-antibody-positive subsets was 4.4/100,000 ([@B25], [@B27]).

Interestingly, the prevalence among Hungarians was slightly higher, at 1.91/100,000 ([@B45]). This has brought up the notion of whether there are some admixtures of Asian genes (from North East Asia) among the Hungarians ([@B53]). Furthermore, there is scarcity of prevalence data from Central Asia, and such data from this region will be informative.

Other Asians
------------

### South Indians

If the 2015 IPND criteria were applied, the prevalence among South Indians in Mangalore was 0.72/100,000 ([@B31]). No cases were found among the 10% South Indian population in Penang Island, Malaysia ([@B39]), suggesting a low prevalence.

### Austronesian Peoples

The Austronesian peoples reside in the Philippines, Malaysia, Indonesia, the Pacific Islands (Polynesia, Micronesia, and Hawaii), down to New Zealand, and also to the west in Madagascar. The study conducted in the multi-racial Penang Island, Malaysia ([@B39]) found that the prevalence of an Austronesian group, the Malays, was \~0.80/100,000 (this was revised from 0.43/100,000 as reported earlier, after a new case was diagnosed). The prevalence data from another Austronesian group was available recently, namely, the Māoris in New Zealand, with an estimated prevalence of 1.50/100,000 ([@B46]). Nevertheless, in the same study, no cases of NMOSD were found among the \~295,000 Pacific Islanders (Pasifika) ([@B46]). More data from other Austronesian groups in other localities will be useful to clarify this.

### Arabs

A study from Abu Dhabi, United Arab Emirates reported six cases of NMOSD among its citizens, consistent with a prevalence of 1.09/100,000 (AQP4-antibody seropositivity: 83%, all six cases were females) ([@B41]). If only adult citizens aged ≥20 years were considered (a total of five cases), the prevalence is higher at 1.76/100,000. Data on Arabs in other regions of Middle East and North Africa will be very informative.

### Australian Aborigines

The Australian Aborigines are one of the oldest populations in the world, with their ancestors having migrated to Australia around 50,000 years ago. There is evidence of some admixture of Denisovan genes in the Aborigines (Denisovans are an extinct species or subspecies of humans of the genus *Homo*). It is interesting to note that MS rarely exists in the Aborigines ([@B54], [@B55]). Recent data showed that NMOSD is also rare among the Aborigines, with a prevalence of 0.38/100,000 ([@B46]). However, the paper cautioned whether inequality in health care access may lead to this low figure.

### Native Americans

MS is less common among Native Americans than in Whites in North America. Prior to AQP4-antibody discovery, a study conducted among the Native Canadians in Manitoba ([@B56]) found seven cases of "MS," of which five cases were of NMO phenotypes, while the other two had brainstem involvement. Autopsy of one patient showed eosinophil infiltration in the cervical cord lesion, and retrospectively, this pathological finding suggests that this case was likely to be NMOSD. Genetically, Native Americans may be more closely related to early East Asians, and thus they may also have a higher prevalence than Whites. A re-look at these native populations will be helpful to confirm the results, though may be practically difficult.

### Latin America

After the arrival of Europeans in the 1500\'s, the indigenous populations of Latin American had dwindled rapidly. Today, along with the indigenous peoples, there is a large proportion of Whites, Blacks, and mixed races in Latin America.

In an earlier study from a tertiary hospital in Mexico City ([@B57]), using 1999 Wingerchuk criteria, a total of 34 cases of NMO were identified, with all patients being Mestizos (mixed race). By calculating the ratio of MS and NMO in the hospital, and by using the estimated MS prevalence in the country at that time, it was extrapolated that the prevalence of NMO among Mexican Mestizos was around 1.3/100,000. With the availability of AQP4-antibody assays, and the newer diagnostic criteria that include NMOSD cases, this prevalence rate is likely to be higher.

From the preliminary findings of a recent study involving seven general hospitals in Venezuela presented at a conference ([@B58]), it was estimated that the prevalence of NMOSD in Venezuela was 2.2/100,000, with a female-to-male ratio of 4:1, and again Mestizos formed the majority of those patients.

Studies from other representative populations will be useful to further inform the prevalence of NMOSD in Latin America.

### North Africa

The populations of North Africa consist mainly of Amazighs (Berbers) and Arabs. As in Whites/Caucasian populations, there appear to be much higher number of MS than NMOSD cases in North Africa ([@B59], [@B60]). There have been no population-based studies on NMOSD in North Africa so far. There is only one population-based study on Arabs in the Middle East (Abu Dhabi) ([@B41]), and the prevalence data among Amazighs are awaited.

Incidence of NMOSD
------------------

[Table 1](#T1){ref-type="table"} summarizes the incidence reported in the available population-based studies. Among Whites, the annual incidence of NMOSD is generally reported to be around 0.5--0.8/million ([@B30], [@B38], [@B42], [@B43]). In populations with a higher prevalence, the incidence is also higher. For instance, Blacks in Martinique have a high prevalence of 11.5/100,000, and its incidence was also reported to be high, at 7.3/million ([@B34]). Recently, the data from South Korea also showed a high incidence, ranging from 4.1 to 7.3/million for the period 2013--2017 ([@B44], [@B48]). Other populations with a prevalence higher than 1/100,000 also reported an incidence higher than 1/million \[for example, 1.16/million in Arabs ([@B41]), and 1.32/million in Hungarians ([@B45])\].

A limitation regarding incidence calculation is that, if a new antibody test becomes available in the study region, or when there is increased awareness among clinicians, then the number of newly diagnosed cases in that particular year will be higher, leading to a higher incidence rate, even though the disease could have started many years earlier in some cases. Nevertheless, if researchers are able to calculate the incidence rates over the past few years (e.g., past 5 years) and average them, it is likely to be more accurate.

For pediatric NMOSD, there were two recent nationwide/region-wide studies that reported on its incidence. In the Danish study, the incidence of pediatric NMOSD was calculated as 0.31/million ([@B61]). In the Taiwanese study using the national health insurance research database, over the period from 2011 to 2015, the average annual incidence was reported as 1.1/million ([@B62]). Again, this higher incidence in Taiwan as compared to Denmark is not surprising as NMOSD is more prevalent among East Asians than Whites.

Age and Racial Differences in the Clinical Features and Severity of NMOSD
-------------------------------------------------------------------------

Some studies have analyzed how the clinical features and disability are affected by onset age and racial differences. Patients with young-onset NMOSD were more likely to have optic neuritis as onset attack, while older-onset patients often developed myelitis as the initial presentation ([@B63]). Furthermore, young-onset patients with optic neuritis were more likely to develop not only recurrent optic neuritis but also higher likelihood of developing blindness, as compared to older-onset patients with optic neuritis ([@B63], [@B64]). Conversely, older-onset patients with myelitis often had poor recovery, while most young-onset patients with myelitis recovered well without permanent motor disability ([@B63], [@B64]).

There also appears to be some differences in the clinical features of NMOSD among different races. Blacks and Asians tended to have lower mean ages at onset than Whites (Blacks: around 28--33 years, Asians: 35--40 years, vs. Whites: 44 years) ([@B63], [@B65]). Black and Asian patients were more likely to have brain and brainstem attacks and abnormalities on brain MRI as compared to Whites ([@B64], [@B65]). Overall, the risk of relapse was lowest in Japanese than in Whites and Blacks ([@B63], [@B64]).

Blacks were found to have a greater likelihood of developing visual disability with time than Whites and Japanese ([@B63], [@B64]). On the other hand, Whites had a higher probability of developing severe motor disability or wheelchair dependence as compared to Japanese ([@B63]). Severe attacks were more frequent in Blacks than in Asians and Whites, and therefore Blacks were at a higher risk of severe disability in the early course of the disease ([@B65]). In a study from the USA, patients with African ancestry were also found to have a higher mortality rate (15.4%) as compared to the overall mortality rate (7.0%) ([@B66]). Nonetheless, while race affected the clinical phenotype, age at onset, and severity of attacks, the overall outcomes were mostly dependent on early and effective immunosuppressive treatment ([@B65]).

MOG-Antibody-Associated Disease: Prevalence and Incidence
---------------------------------------------------------

After the discovery of the AQP4 antibody, a majority of NMO cases have been found positive for this antibody. Nevertheless, there is still a proportion of cases with an NMO phenotype that are persistently tested negative for AQP4 antibody, despite using the most sensitive cell-based assays available. It was later realized that some of these AQP4-antibody-negative NMOSD cases were in fact seropositive for MOG antibody. This so-called MOG-antibody-associated disease consists of a significant proportion of NMOSD cases that are AQP4-antibody seronegative, ranging from 7 to 42% ([@B7], [@B67]--[@B70]).

Interestingly, for MOG-antibody-associated disease, besides NMO phenotype, optic neuritis, and myelitis, some of these MOG-antibody-positive cases also have clinical phenotypes beyond the current NMOSD spectrum, such as ADEM/MDEM-like presentation ([@B71]), cerebral cortical encephalitis ([@B12]), and cranial nerve involvement ([@B14]). Pathologically, MOG-antibody-associated disease is a type of demyelinating disease, as opposed to astrocytopathic disease seen in AQP4-antibody-positive NMOSD ([@B72], [@B73]).

A recent Dutch nationwide study reported the incidence of MOG-antibody-associated disease as 1.6/million, with 1.3/million in adults, and a higher incidence of 3.1/million in children ([@B74]). It should be noted that this incidence rate of 1.6/million is higher than the incidence rate of 0.5--0.8/million in NMOSD (mostly AQP4-antibody-positive) among Whites.

So far, hospital-based studies largely did not observe any significant racial preponderance for MOG-antibody-associated disease. For instance, in the UK cohort, the racial breakdown was as expected in the general population ([@B9]). Nevertheless, from the annual report of the Oxford NMO Service, there were 145 patients with AQP4-antibody-positive NMOSD, 111 patients with MOG-antibody disease, and 28 patients who were double-seronegative. The proportion of MOG-antibody disease within the NMOSD spectrum was rather significant ([@B75]). Additionally, a study from Mayo Clinic on AQP4- and MOG-antibody testing for 15,598 patients showed higher positivity rate for MOG antibody (1291 patients, 8.3%) than for AQP4 antibody (387 patients, 2.3%). Of the adults, 6.5% were MOG-antibody positive vs. 2.6% for AQP4 antibody, while in children, 21.1% were positive for MOG antibody as compared to 1.9% for AQP4 antibody ([@B76]). Similarly, one study in Sri Lanka, in collaboration with the Mayo Clinic, also reported more MOG-antibody-positive cases (126 patients) than AQP4-antibody-positive cases (36 patients) ([@B77]). On the other hand, MOG-antibody-associated disease was relatively uncommon in the non-Caucasian population in Rio de Janeiro (Brazil) ([@B70]).

The preliminary findings of a population-based prevalence study of MOG-antibody-associated disease, jointly conducted at Olmsted county (USA) and Martinique Island, were recently presented at a conference (ECTRIMS 2019) ([@B78]). In Olmsted county, the prevalence was calculated to be 3.42/100,000, with an incidence of 2.39/million, while at Martinique, the prevalence was 1.6/100,000, with an incidence of 1.12/million.

In the Catalonia NMOSD prevalence study, 12% of cases were MOG-antibody-positive ([@B38]). However, the cases in this study were required to strictly fulfill the 2015 IPND criteria, and thus only those with an NMO phenotype were analyzed (The prevalence of MOG-antibody-positive NMO was calculated to be 0.11/100,000.). Needless to say, if MOG-antibody-positive cases with optic neuritis alone or myelitis alone and those with ADEM-like presentation are included, the prevalence of MOG-antibody disease is likely to be higher.

More data from different geographical areas are clearly in need to further inform about the prevalence and incidence of MOG-antibody-associated disease.

Some demographic and epidemiological data and clinical features of AQP4-antibody-positive NMOSD and MOG-antibody-associated disease in comparison with MS are shown in [Table 2](#T2){ref-type="table"}.

###### 

Epidemiological and clinical comparison between AQP4-antibody-seropositive NMOSD, MOG-antibody disease, and MS.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                            **AQP4-antibody disease**                                                                    **MOG-antibody disease**                                                                                                                                         **MS**
  ------------------------- -------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------
  Mean age at onset         40 years                                                                                     More common in children than in adults                                                                                                                           30 years

  Female:male ratio         9:1                                                                                          Around 1:1                                                                                                                                                       2--4:1

  North--South gradient     No increased prevalence with increasing latitude                                             No data                                                                                                                                                          Increased prevalence with increasing latitude from the equator (either toward North or South)

  Prevalence                East Asians: 3.5/100,000\                                                                    More common in children than in adults                                                                                                                           Up to 100--200/100,000 in White populations, but \<5--50/100,000 in many Asian and African countries Rising in most parts of the world
                            Whites: 1/100,000\                                                                                                                                                                                                                                            
                            Blacks: range from 1.8 to 10/100,000                                                                                                                                                                                                                          

  Annual incidence          Around 0.5--0.8/million in Whites\                                                           Dutch nationwide study: 1.6/million; adults: 1.3/million; children: 3.1/million\                                                                                 Up to 100/million in White populations, but was low in many equatorial countries
                            Higher annual incidence in non-White populations                                             More data are needed                                                                                                                                             

  Disease course            Relapsing                                                                                    Monophasic or relapsing                                                                                                                                          Relapsing, with the majority eventually converting to a secondary progressive disease\
                                                                                                                                                                                                                                                                                          Up to 15% are primary progressive in Whites

  Clinical manifestations   Optic neuritis\                                                                              Optic neuritis\                                                                                                                                                  Optic neuritis\
                            Myelitis\                                                                                    Myelitis\                                                                                                                                                        Myelitis\
                            Area postrema syndrome\                                                                      ADEM/MDEM\                                                                                                                                                       Brain syndromes
                            Other brain syndromes                                                                        Brainstem/cerebral cortical encephalitis\                                                                                                                        
                                                                                                                         Cranial nerve involvement                                                                                                                                        

  Optic neuritis            Unilateral/chiasmal, long (\>1/2 of optic nerve)                                             Unilateral/simultaneous bilateral, long; frequent optic disc swelling (papillitis)                                                                               Unilateral, short

  Myelitis                  Long (\>3 vertebral segments) in 85%; centrally located; affects cervical or thoracic cord   Often long, but may be \<3 vertebral segments; gadolinium enhancement less common than AQP4-antibody disease; relatively more common in the lumbosacral region   Non-transverse, short; peripheral/dorsolateral

  Attack severity           Moderate to severe                                                                           Mild to moderate                                                                                                                                                 Mild to moderate

  Recovery                  Variable, but commonly poor                                                                  Fair to good                                                                                                                                                     Fair to good

  Disability                Attack-related                                                                               Attack-related                                                                                                                                                   Mainly due to progression

  Pathology                 Astrocytopathy                                                                               Demyelination                                                                                                                                                    Demyelination

  Treatment                 Immunosuppressants; some MS drugs may be harmful                                             Consider immunosuppressants if recurrent; some MS drugs may be ineffective                                                                                       MS disease-modifying drugs
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*ADEM/MDEM, acute disseminated encephalomyelitis/multiphasic disseminated encephalomyelitis; AQP4, aquaporin 4; MOG, myelin oligodendrocyte glycoprotein; MS, multiple sclerosis; NMOSD, neuromyelitis optica spectrum disorder*.

Conclusion {#s2}
==========

There appears to be varying prevalence rates of NMOSD, most cases of which are AQP4-antibody-positive cases, among the different racial groups worldwide, with East Asians and Blacks having a higher prevalence than Whites. In most regions, these prevalence rates are lower than that of MS. In AQP4-antibody-positive NMOSD, female preponderance is definite (up to 90%) and the majority of the cases are adults. Moreover, the clinical features of NMOSD and disability accrual may be influenced by onset age and race. The data suggest that certain genetic and environmental factors associated with race may be involved in the pathogenesis of NMOSD. More well-designed population-based and longitudinal studies in different geographical areas and racial groups will be useful to clarify the issue, and to shed new lights onto this unique neuroinflammatory disease. Among AQP4-antibody-negative NMOSD, some patients are MOG-antibody-positive, and unlike AQP4-antibody-positive NMOSD, males, and females are equally affected by MOG-antibody-associated disease and the prevalence may be higher in children than in adults. However, the prevalence data of MOG-antibody-associated disease including the ones with an NMOSD phenotype are still insufficient and being accumulated. Accessibility to AQP4-antibody and MOG-antibody testing, which is currently limited in many regions, is a challenge to overcome.

Author Contributions {#s3}
====================

JH conceived and designed the study, drafted the manuscript, contributed to data acquisition, and critically revised the manuscript for intellectual content. NA, IN, SB, ML, NK, AJ, RM, BW, FP, SP, JP, DW, JB, and MY made substantial contribution to the intellectual content, contributed to data acquisition, and critically revised the manuscript for intellectual content. KF supervised the study, conceived and designed the study, drafted the manuscript, contributed to data acquisition, and critically revised the manuscript for intellectual content. All authors approved the final manuscript.

Conflict of Interest {#s4}
====================

JH, NA, NK, AJ, RM, and JB report no disclosures related to this work. IN has received speaker honoraria and travel funding from Mitsubishi Tanabe Pharma, Biogen Japan, and Novartis Pharmaceuticals, and received research support from LSI Medience Corporation, and has been funded by JSPS KAKENHI Grant Number 17K09772. SB has received honoraria for attendance at advisory boards and travel sponsorship from Bayer-Scherring, Biogen-Idec, Merck-Serono, Novartis, and Sanofi-Genzyme; has received speakers honoraria from Biogen-Idec and Genzyme; is an investigator in clinical trials sponsored by Biogen Idec, Novartis, and Genzyme; and was the recipient of an unencumbered research grant from Biogen-Idec. ML was partly supported by an NHS England highly specialized commissioning group for a neuromyelitis service. She has received support for scientific meetings and honoraria for presentations from Biogen Idec and Novartis and for advisory work from Viela Bio. BW has received royalties from RSR Ltd, Oxford University, Hospices Civil de Lyon, and MVZ Labor PD Dr. Volkmann und Kollegen GbR for a patent of NMO-IgG as a diagnostic test for NMO and related disorders, served on adjudication committee for clinical trials in NMO being conducted by MedImmune and Alexion, and consulted for Chugai, Mitsubishi-Tanabe regarding a clinical trial for NMO. FP has received research support from DFG, BMBF, KKNMS, and the Guthy-Jackson Charitable Foundation. He serves on steering committees of the OCTIMS study (Novartis) and the N-Momentum study (Viela Bio) and has received personal compensation and research support from Alexion, Bayer, Biogen, Roche, Merck, Teva, Shire, Celgene, Novartis, and Sanofi Genzyme. He is an associate editor of Neurology: Neuroimmunology and Neuroinflammation. SP has received grants, personal fees, non-financial support, honorarium, and travel expenses for speaking from Alexion Pharmaceuticals and the Guthy-Jackson Charitable Foundation paid to his institution; grants from Grifols, the National Institutes of Health, and Autoimmune Encephalitis Alliance paid to his institution; consulting fees from Euroimmun paid to his institution; and grants, personal fees, non-financial support, and honorarium from MedImmune; served on the advisory board of Alexion Pharmaceuticals; holds patent 8,889,102 and 9,891,219B2; and has patents pending for GFAP-IgG, Septin-5-IgG, MAP1B-IgG, Kelch-like protein 11, and PDE10A. JP was partly funded by highly specialized services to run a national congenital myasthenia service and a neuromyelitis service. She has received support for scientific meetings and honoraria for advisory work from Merck Serono, Biogen Idec, Novartis, Teva, Chugai, Bayer Schering, Alexion, Roche, Genzyme, MedImmune, EuroImmun, MedDay, Abide ARGENX, UCB, and Viela Bio, and grants from Merck Serono, Novartis, Biogen Idec, Teva, Abide, MedImmune, Bayer Schering, Genzyme, Chugai, and Alexion. She has received grants from the MS society, Guthy-Jackson Charitable Foundation, NIHR, Oxford Health Services Research Committee, EDEN, MRC, GMSI, John Fell, and Myaware for research studies. DW has received research support from Alexion and TerumoBCT and honoraria from MedImmune, Novartis, Biogen, Celgene, Genentech, TG Therapeutics, Arcus Medica, Third Rock Ventures, and Reistone. MY is founder of NovaDigm Therapeutics, Inc, and Metacin, Inc. He is a member of the Genentech Scientific Advisory Committee, and has received travel expenses or honoraria from Genentech and Alexion. KF has received grants from Ministry of Education, Science and Technology of Japan and Ministry of Health, Welfare, and Labor of Japan, and received honoraria, and/or travel expenses for speaking, and/or advisory boards from Mitsubishi Tanabe, Biogen, Bayer, Takeda, Novartis, Alexion, VielaBio, Asahi Kasei, Dainihon Sumitomo, Eisai, Teijin, Ono, Roche, and Chugai.

Active members of the Guthy-Jackson Charitable Foundation (GJCF) International Clinical Consortium for NMOSD (in alphabetical order as of March 2020): Hesham Abboud (Case Western Reserve University, Cleveland, OH, USA); Orhan Aktas (Institute of Neuroimmunology, Düsseldorf, Germany); Raed Alroughani (Amiri Hospital, Kuwait City, Kuwait); Ayse Altintas (Koc University School of Medicine, Istanbul, Turkey); Lilyana Amezcua (University of Southern California, Los Angeles, CA, USA); Metha Apiwattanakul (Prasat Neurological Institute, Bangkok, Thailand); Nasrin Asgari (University of Southern Denmark, Odense, Denmark); Brenda Banwell (The Children\'s Hospital of Philadelphia, University of Pennsylvania, PA, USA); Terrence M. Blaschke \[Stanford University (Emeritus), Palo Alto, CA, USA\]; Jeffrey Bennett (University of Colorado, Denver, CO, USA); Denis Bichuetti (Universidade Federal de São Paulo, São Paulo, Brazil); James Bowen (Swedish Neuroscience Institute, Seattle, WA, USA); Alexey Boyko (Prigov\'s Russian Scientific Research Medical University, Moscow, Russia); Alexander Brandt (University of California, Irvine, CA, USA); Simon A. Broadley (Griffith University, Southport, QLD, Australia); Wolfgang Brück (University Medical Center Göttingen, Göttingen, Germany); Edgar Carnero Contentti (Hospital Alemán, Buenos Aires, Argentina); Robert Carruthers (University of British Columbia, Vancouver, Canada); Tanuja Chitnis (Brigham and Women\'s Hospital and Massachusetts General Hospital, Boston, MA, USA); Jeffrey Cohen (Cleveland Clinic, Cleveland, OH, USA); Guillermo Delgado-García (National Autonomous University of Mexico, Mexico City, Mexico); Irena Dujmovic Basuroski (UNC School of Medicine, Chapel Hill, NC, USA); Nikos Evangelou (University of Nottingham, Nottingham, UK); Kazuo Fujihara (Fukushima Medical University, Fukushima, Japan); Andrew Goodman (University of Rochester, Rochester, NY, USA); Benjamin Greenberg (University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA); Yael Hacohen (Great Ormond Street Hospital/UCL, London, UK); May Han (Stanford University School of Medicine, Stanford, CA, USA); Joachim Havla (Ludwig-Maximilians University, Munich, Germany); Kerstin Hellwig (St. Josef Hospital Bochum, Bochum, Germany); Jyh Yung Hor (Penang General Hospital, Penang, Malaysia); Raffaele Iorio (Institute of Neurology, Catholic University of Sacred Heart, Rome, Italy); Anu Jacob (Walton Centre, Liverpool, UK); Sven Jarius (University of Heidelberg, Heidelberg, Germany); Jorge Andres Jimenez Arango (Universidad de Antioquia, Medellin, Colombia); Ilana Katz-Sand (Icahn School of Medicine at Mount Sinai, New York, NY, USA); Ho Jin Kim (National Cancer Center, Goyang, Republic of Korea); Sung Min Kim (Seoul National University Hospital, Seoul, Republic of Korea); Dorlan Kimbrough (Brigham and Women\'s Hospital and Massachusetts General Hospital, Boston, MA, USA); Najib Kissani (Neurology Department, University Hospital, Marrakech, Morocco); Ilya Kister (NYU, Langone Medical Center, NY, USA); Eric Klawiter (Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA); Ingo Kleiter (Marianne-Strauß-Klinik, Berg, Germany); Marco Lana-Peixoto (Universidade Federal de Minas Gerais, Belo Horizonte, Brazil); M. Isabel Leite (University of Oxford, Oxford, UK); Michael Levy (Massachusetts General Hospital, Boston, MA, USA); Yaou Liu (Xuanwu Hospital, Capital Medical University, Beijing, China); Fred Lublin (Icahn School of Medicine at Mount Sinai, New York, NY, USA); Youssoufa Maiga (Teaching Hospital Gabriel Touré, Bamako, Mali); Yang Mao-Draayer (University of Michigan, Ann Arbor, MI, USA); Romain Marignier (CHU Lyon, Lyon, France); Sara Mariotto (University of Verona, Verona, Italy); Marcelo Matiello (Brigham and Women\'s Hospital and Massachusetts General, Boston, MA, USA); Maureen Mealy (Viela Bio, Baltimore, MD, USA); Esther Melamed (UT Austin, Austin, TX, USA); Callene Momtazee (University of California Los Angeles, CA, USA); Ichiro Nakashima (Tohoku Medical and Pharmaceutical University, Sendai, Japan); Jayne Ness (Children\'s of Alabama**---**Neurology, AL, USA); Kevin O\'Connor (Yale University School of Medicine, New Haven, CT, USA); Celia Oreja-Guevara (Hospital Clínico San Carlos, Madrid, Spain); Jacqueline Palace (University of Oxford, Oxford, UK); Lekha Pandit (K S Hegde Medical Academy, Mangalore, India); Friedemann Paul (Charité University Medicine Berlin, Berlin, Germany); Sarah Planchon Pope (Cleveland Clinic, Cleveland, OH, USA); Anne-Katrin Pröbstel (University Hospital Basel, Basel, Switzerland); Peiqing Qian (Swedish Neuroscience Institute, Seattle, WA, USA); Chao Quan (Huashan Hospital, Shanghai, China); Pavle Repovic (Swedish Neuroscience Institute, Seattle, WA, USA); Claire Riley (Columbia University, New York, NY, USA); Marius Ringelstein (Heinrich-Heine-University, Düsselforf, Germany); Victor Rivera (Houston Methodist Hospital, Houston, TX, USA); Dalia Rotstein (St. Michael\'s Hospital, Toronto, Canada); Klemens Ruprecht (Charité University Medicine Berlin, Berlin, Germany); Maria José Sá (Centro Hospitalar São João, Porto, Portugal); Albert Saiz (IDIBAPS, Hospital Clinic of Barcelona, Barcelona, Spain); Douglas Sato (Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil); Ché Serguera (MIRCen INSERM/CEA, Paris, France); Eslam Shosha (Prince Sultan Military Medical City, Riyadh, Saudi Arabia); Nancy Sicotte (Cedars Sinai, Los Angeles, CA, USA); Sasitorn Siritho (Mahidol University, Bangkok, Thailand); Aksel Siva (Istanbul University, Cerrahpaşa School of Medicine, Istanbul, Turkey); Terry J. Smith (University of Michigan, Ann Arbor, MI, USA); Ibis Soto de Castillo (Hospital Universitario de Maracaibo, Maracaibo, Venezuela); Silvia Tenembaum (Hospital de Pediatria, Buenos-Aires, Argentina); Leticia Tornes (University of Miami, FL, USA); Pablo Villoslada (Stanford University School of Medicine, Stanford, CA, USA); Brian G. Weinshenker (Mayo Clinic, Rochester, MN, USA); Dean M. Wingerchuk (Mayo Clinic, Scottsdale, AZ, USA); Jens Würfel (MIAC AG, Basel, Switzerland); Bassem Yamout (American University of Beirut Medical Center, Beirut, Lebanon); Michael R. Yeaman (University of California, Los Angeles, Los Angeles, CA, USA); Ann Yeh (Sick Kids Hospital, Toronto, Canada); and Scott Zamvil (University of California San Francisco, CA, USA).

[^1]: Edited by: Su-Hyun Kim, National Cancer Center, South Korea

[^2]: Reviewed by: Kok Pin Yong, National Neuroscience Institute (NNI), Singapore; Merja Hannele Soilu-Hänninen, University of Turku, Finland

[^3]: This article was submitted to Neuroepidemiology, a section of the journal Frontiers in Neurology

[^4]: †Active members of the Guthy-Jackson Charitable Foundation (GJCF) International Clinical Consortium for NMOSD (in alphabetical order as of March 2020) are listed in the Acknowledgments
